Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Pfizer fell 31 cents (-1.1%) to $27.94 on average volume. Throughout the day, 29.1 million shares of Pfizer exchanged hands as compared to its average daily volume of 31.7 million shares. The stock ranged in price between $27.88-$28.23 after having opened the day at $28.23 as compared to the previous trading day's close of $28.25. Other companies within the Drugs industry that declined today were: Delcath Systems ( DCTH), down 10.3%, XenoPort ( XNPT), down 10.1%, Novogen ( NVGN), down 9.1%, and Simcere Pharmaceutical Group ( SCR), down 8.5%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $202.66 billion and is part of the health care sector. The company has a P/E ratio of 22.4, above the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.